Myelin Volume Measurement Tool Receives CE Mark
By MedImaging International staff writers Posted on 25 Apr 2017 |
Image: The top images show conventional 1.5T MRI exams, and the lower images show SyMRI exams synthesized in a single scan (Photo courtesy of SyntheticMR).
A tool that can be used for rapid quantification of the estimated myelin volume in the brain for diagnostic imaging has been awarded the CE-mark (Conformité Européenne) for clinical use in Europe.
According to the developer of the post-processing software, the tool is compatible with Magnetic Resonance (MR) scanners from leading vendors.
The Rapid Estimation of Myelin for Diagnostic Imaging (REMyDI) tool is part of the SyntheticMR SyMRI NEURO REMyDI post-processing software package. Myelin quantification enables clinicians to monitor myelin degeneration in patients with neurodegenerative disorders, and diseases that cause brain demyelination. Clinicians can also use the tool to follow myelination in the developing brain. The new REMyDI feature will provide clinicians with automatic myelin volume measurement using data from a single 5-6-minute quantitative MRI scan. Post-processing is automatic and takes less than 10 seconds to complete.
The SyMRI software package enables clinicians to capture multiple image contrasts in one MR scan. The contrast can be adjusted following the scan to create additional images. The system provides automatic segmentation of brain tissue for objective decision support based on quantitative data. Scanner settings can be matched between scans to enable accurate comparison between exams. The images can also be matched with previous images, and conventional protocols. The SyMRI software package is CE-marked, and is pending 510(k) approval from the US Food and Drug Administration (FDA).
According to the developer of the post-processing software, the tool is compatible with Magnetic Resonance (MR) scanners from leading vendors.
The Rapid Estimation of Myelin for Diagnostic Imaging (REMyDI) tool is part of the SyntheticMR SyMRI NEURO REMyDI post-processing software package. Myelin quantification enables clinicians to monitor myelin degeneration in patients with neurodegenerative disorders, and diseases that cause brain demyelination. Clinicians can also use the tool to follow myelination in the developing brain. The new REMyDI feature will provide clinicians with automatic myelin volume measurement using data from a single 5-6-minute quantitative MRI scan. Post-processing is automatic and takes less than 10 seconds to complete.
The SyMRI software package enables clinicians to capture multiple image contrasts in one MR scan. The contrast can be adjusted following the scan to create additional images. The system provides automatic segmentation of brain tissue for objective decision support based on quantitative data. Scanner settings can be matched between scans to enable accurate comparison between exams. The images can also be matched with previous images, and conventional protocols. The SyMRI software package is CE-marked, and is pending 510(k) approval from the US Food and Drug Administration (FDA).
Latest MRI News
- Combining MRI with PSA Testing Improves Clinical Outcomes for Prostate Cancer Patients
- PET/MRI Improves Diagnostic Accuracy for Prostate Cancer Patients
- Next Generation MR-Guided Focused Ultrasound Ushers In Future of Incisionless Neurosurgery
- Two-Part MRI Scan Detects Prostate Cancer More Quickly without Compromising Diagnostic Quality
- World’s Most Powerful MRI Machine Images Living Brain with Unrivaled Clarity
- New Whole-Body Imaging Technology Makes It Possible to View Inflammation on MRI Scan
- Combining Prostate MRI with Blood Test Can Avoid Unnecessary Prostate Biopsies
- New Treatment Combines MRI and Ultrasound to Control Prostate Cancer without Serious Side Effects
- MRI Improves Diagnosis and Treatment of Prostate Cancer
- Combined PET-MRI Scan Improves Treatment for Early Breast Cancer Patients
- 4D MRI Could Improve Clinical Assessment of Heart Blood Flow Abnormalities
- MRI-Guided Focused Ultrasound Therapy Shows Promise in Treating Prostate Cancer
- AI-Based MRI Tool Outperforms Current Brain Tumor Diagnosis Methods
- DW-MRI Lights up Small Ovarian Lesions like Light Bulbs
- Abbreviated Breast MRI Effective for High-Risk Screening without Compromising Diagnostic Accuracy
- New MRI Method Detects Alzheimer’s Earlier in People without Clinical Signs